Ligand Pharma (LGND) Tops Q4 EPS by 17c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $288.83 +1.13%
Revenue Growth %: -32.2%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -32.2%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.31, $0.17 better than the analyst estimate of $1.14. Revenue for the quarter came in at $50.5 million versus the consensus estimate of $47.82 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- BMO Capital Starts American Eagle Outfitters (AEO) at Market Perform
- Activist investor presses Xerox to review financial services arm - Bloomberg
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
